Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

Inclusion Criteria:

- - Informed consent obtained before any trial-related activities. Trial-related
activities are any procedures that are carried out as part of the trial, including
activities to determine suitability for the trial

- - Subjects diagnosed with type 2 diabetes and treated with metformin equal to or above
1500 mg/day (or maximum tolerated dose equal to or above 1000 mg/day) and sitagliptin
100 mg/day, both at a stable dose for at least 90 days prior to screening. Stable is
defined as unchanged medication and dose

- - HbA1c 7.5% - 9.5% (58 mmol/mol - 80 mmol/mol) (both inclusive)

- - Body mass index equal to or above 20 kg/m^2

Exclusion Criteria:

- - Any chronic disorder or severe disease which at the discretion of the investigator
might jeopardise subject's safety or compliance with the protocol

- - Treatment with glucose lowering agent(s) other than stated in the inclusion criteria
in a period of 90 days prior to screening. An exception is short-term treatment (equal
to or less than 7 days in total) with insulin in connection with intercurrent illness

- - Female who is pregnant, breast-feeding, intends to become pregnant or of
child-bearing potential not using adequate contraceptive methods (adequate
contraceptive measures as required by local regulations or practice)

- - History of chronic pancreatitis or idiopathic acute pancreatitis

- - Screening calcitonin value equal to or above 50 ng/L

- - Personal or family history of medullary thyroid carcinoma or multiple endocrine
neoplasia syndrome type 2

- - Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin
cancer or squamous cell skin cancer)

- - Impaired liver function, defined as alanine aminotransferase equal to or above 2.5
times upper normal limit

- - Impaired renal function defined as estimated glomerular filtration rate 60
mL/min/1.73 m^2 per modification of diet in renal disease formula

- - Any episode of unstable angina, acute coronary event, cerebral stroke/transient
ischemic attack or other significant cardiovascular event as judged by the
investigator within 90 days prior to screening

- - Heart failure, New York Heart Association class IV

- - Uncontrolled treated or untreated hypertension (systolic blood pressure equal to or
above 180 mmHg and/or diastolic blood pressure equal to or above 100 mmHg)